Lupin Recalls Moxifloxacin Ophthalmic Solution Due to Stability Test Failure
Lupin Pharmaceuticals is recalling Moxifloxacin Ophthalmic Solution because an out-of-specification result was found in a stability study. The product was distributed throughout the United States.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Lupin Pharmaceuticals Inc. is recalling Moxifloxacin Ophthalmic Solution USP, 0.5%, 5 mL bottles. The recall involves 13,896 bottles with Lot # H800393 and an expiration date of 01/2020. The product is a prescription ophthalmic solution manufactured for Lupin Pharmaceuticals Inc. in Baltimore, Maryland, and manufactured by Lupin Limited in India.
The recall was initiated due to a failed impurities/degradation specification. Specifically, an out-of-specification result was identified in the related substance test during a three-month long-term stability study. The FDA has classified this recall as Class III, indicating that use of, or exposure to, the violative product is not likely to cause adverse health consequences.
The product was distributed throughout the United States. Consumers and healthcare providers should stop using the affected product and contact their healthcare provider or pharmacist for further instructions or a replacement.
The recalled product
- Product
- MOXIFLOXACIN (MOXIFLOXACIN)
- Brand
- MOXIFLOXACIN
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Category
- Drug — Ophthalmic
- Hazard
- Affected units
- 13,896
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: H800393
- Exp. 01/2020
UPCs (1)
- 0368180422013
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · MOXIFLOXACIN
- ModerateMoxifloxacin Ophthalmic Solution Recall for Failed Impurities Specifications
FDA (Drugs) · 2022-02-23
- LowAuroMedics Recalls Moxifloxacin Ophthalmic Solution Due to Discoloration
FDA (Drugs) · 2020-01-22
- LowLupin Recalls Moxifloxacin Ophthalmic Solution Due to Impurity Levels
FDA (Drugs) · 2019-03-06
- ModerateLupin Recalls Moxifloxacin Ophthalmic Solution Due to Stability Test Failures
FDA (Drugs) · 2019-02-20
Same manufacturer · Lupin Pharmaceuticals Inc.
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateSertraline tablets recalled because bottle seals are not adhering
FDA (Drugs) · 2025-12-17
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17